로딩 중…
StockDiggingStockDigging

Daehan Nupharm Co.,Ltd.

054670· KOSDAQ
₩5,670-2.58%
2026-06-19

Price Chart

Daehan Nupharm Co.,Ltd.-27.40%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap81.39B KRW
Revenue205.39B KRW
Net Income7.48B KRW
Total Assets275.89B KRW
Net Assets138.21B KRW
Employees397
Value
P/E10.88x
P/B0.59x
PEG0.67x
P/S0.40x
EV/EBITDA224.07x
FCF Yield-42.44%
Profitability
ROE5.41%
ROA2.71%
Op. Margin0.60%
Revenue Growth5.76%
Earnings Growth16.28%
Financial Health
Debt Ratio199.62%
Total Debt213.38B KRW
FCF-34.54B KRW
Cash18.94B KRW
Current Ratio1.57x
Dividend
Div. Yield1.72%
Div. Growth0.00%
Performance
1Y Return-27.40%
1M Return-8.40%
From 52W High-35.64%
1Y MDD-33.17%
Trading
Volume44,340 shares
Foreign Own.0.55%
Per Share
EPS1,092 KRW
BPS9,847 KRW

Company Info

CEO 이원석
Employees 397
Founded 1984
HQ 경기도 화성시, KR

Established in 1984 and listed on KOSDAQ in 2002, Daehan Newpharm is a pharmaceutical company headquartered in Hwaseong-si, Gyeonggi-do. It focuses on specialty pharmaceuticals for metabolic diseases like hypertension and diabetes, as well as digestive ulcer treatments, while strengthening non-reimbursable products such as obesity treatments, vitamins, and immune enhancers. The company diversifies into animal pharmaceuticals, developing pet products and farm environment improvers, and expands its bio business into stem cell-based anti-aging agents and cell therapies.